Lexeo COO acquires 2,110 shares, gets stock option

The option’s underlying shares vest and become exercisable 25% on September 24, 2027, then 1/48th monthly thereafter, subject to continuous service.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero acquired 2,110 common shares under the 2023 Employee Stock Purchase Plan on September 14, 2026, at $2.644 per share. His reported common-stock holdings afterward were 138,288 shares, including 97,026 Restricted Stock Units. On September 24, 2026, he received an option covering 54,750 common shares at a $3.39 exercise price, expiring September 23, 2036. 25% of the underlying shares vest and become exercisable on September 24, 2027; 1/48th vests monthly thereafter, subject to continuous service. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Grant/Award: 56,860 shares

Grant/Award 2 txns

Insider Otero Jose Manuel

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F3	54,750	$0.00	$0.00
Grant/Award	Common Stock F1, F2	2,110	$2.644	$6K

Holdings After Transaction: Stock Option (right to buy) — 54,750 contracts (Direct); Common Stock — 138,288 shares (Direct)

Footnotes (3)

1. F1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
2. F2. Includes 97,026 Restricted Stock Units.
3. F3. 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Key Figures

Common shares acquired: 2,110 shares Acquisition price: $2.644 per share Reported common-stock holdings: 138,288 shares +3 more

6 metrics

Common shares acquired 2,110 shares Under the 2023 Employee Stock Purchase Plan on September 14, 2026

Acquisition price $2.644 per share 2023 Employee Stock Purchase Plan acquisition on September 14, 2026

Reported common-stock holdings 138,288 shares After the September 14, 2026 acquisition; includes 97,026 Restricted Stock Units

Restricted Stock Units 97,026 units Included in reported common-stock holdings

Option award 54,750 underlying common shares Awarded September 24, 2026

Option exercise price $3.39 per share Option covering 54,750 common shares

Key Terms

Employee Stock Purchase Plan, Restricted Stock Units, vest and become exercisable, Rule 16b-3(c), +1 more

5 terms

Employee Stock Purchase Plan financial

"2023 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Restricted Stock Units financial

"Includes 97,026 Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vest and become exercisable technical

"shares underlying the option vest and become exercisable"

Rule 16b-3(c) regulatory

"exempt under both Rule 16b-3(c)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

Rule 16b-3(d) regulatory

"and Rule 16b-3(d)"

Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LXEO shares did Jose Manuel Otero acquire under the employee stock purchase plan?

Jose Manuel Otero acquired 2,110 common shares under Lexeo Therapeutics’ 2023 Employee Stock Purchase Plan on September 14, 2026, at $2.644 per share. His reported common-stock holdings after the acquisition were 138,288 shares, including 97,026 Restricted Stock Units.

What are the terms of Jose Manuel Otero’s LXEO stock option award?

He received an option covering 54,750 common shares on September 24, 2026, with a $3.39 per-share exercise price and an expiration date of September 23, 2036. 25% of the underlying shares vest and become exercisable on September 24, 2027; 1/48th vests monthly thereafter, subject to continuous service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 05:15 PM Accepted by SEC EDGAR 09/28/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Otero Jose Manuel

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		A	V	2,110(1)	A	$2.644	138,288(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.39	09/24/2026		A		54,750		(3)	09/23/2036	Common Stock	54,750	$0	54,750	D

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

2. Includes 97,026 Restricted Stock Units.

3. 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

	/s/ Youjin Choi, Attorney-in-Fact	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)